Lead Product(s) : Budesonide,Formoterol Fumarate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BREZTRI met Primary Endpoints in KALOS and LOGOS Phase III Trials in Asthma
Details : Breztri Aerosphere is a investigational combination of budesonide, a corticosteroid, glycopyrrolate, an anticholinergic and formoterol fumarate, a long-acting beta2-adrenergic agonist, for asthma.
Product Name : Breztri Aerosphere
Product Type : Steroid
Upfront Cash : Inapplicable
May 02, 2025
Lead Product(s) : Budesonide,Formoterol Fumarate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mepolizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Reviews GSK’s Nucala Expansion for COPD Treatment
Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated for the treament of COPD with an eosinophilic phenotype.
Product Name : Nucala
Product Type : Antibody
Upfront Cash : Inapplicable
March 24, 2025
Lead Product(s) : Mepolizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Depemokimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK to Approach FDA With Positive Phase III Data For Long-Acting Asthma Med
Details : GSK3511294 (depemokimab) is the first ultra-long-acting biologic with a binding affinity for IL-5. It is being evaluated for the treatment of severe asthma With an eosinophilic phenotype.
Product Name : GSK3511294
Product Type : Antibody
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : Depemokimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Oaktree Capital
Deal Size : $650.0 million
Deal Type : Financing
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Details : The proceeds will support Verona’s commercial launch of RPL554 (ensifentrine), a first-in-class product under review by the US FDA for COPD maintenance treatment.
Product Name : Ohtuvayre
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Oaktree Capital
Deal Size : $650.0 million
Deal Type : Financing
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Airsupra Demonstrates Significant Reduction in Severe Exacerbations in Asthma Patients
Details : Airsupra (albuterol/budesonide) formerly known as PT027, is a first-in-class SABA/ICS. It is being investigated in patients with intermittent or mild persistent asthma.
Product Name : Airsupra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2024
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mepolizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK's Asthma Drug Nucala Meets Main Goal in Study on Treating Smoker's Lungs
Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated in adults with chronic obstructive pulmonary disease (COPD).
Product Name : Nucala
Product Type : Antibody
Upfront Cash : Inapplicable
June 09, 2024
Lead Product(s) : Mepolizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Depemokimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK announces positive results from ph III severe asthma trials of depemokimab
Details : GSK3511294 (depemokimab) is the first ultra-long-acting biologic with a binding affinity for IL-5. It is being evaluated for the treatment of severe asthma With an eosinophilic phenotype.
Product Name : GSK3511294
Product Type : Antibody
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : Depemokimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Oxford Finance
Deal Size : Undisclosed
Deal Type : Financing
Verona Pharma Secures Debt Facility Of Up to $400 Million
Details : The proceeds will support Verona’s commercial launch of RPL554 (ensifentrine), a first-in-class product under review by the US FDA for COPD maintenance treatment.
Product Name : Ohtuvayre
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Oxford Finance
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Product Name : Ohtuvayre
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Product Name : Ohtuvayre
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable